Stevanato Group S.p.A.
General ticker "STVN" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $6.3B (TTM average)
Stevanato Group S.p.A. follows the US Stock Market performance with the rate: 30.8%.
Estimated limits based on current volatility of 2.7%: low 20.03$, high 21.13$
Factors to consider:
- Company pays dividends (irregularly): last record date 2025-06-05, amount 0.06$ (Y0.30%)
- Total employees count: 4652 as of 2021
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [14.22$, 23.63$]
- 2025-12-31 to 2026-12-31 estimated range: [14.82$, 24.42$]
Financial Metrics affecting the STVN estimates:
- Positive: with PPE of 41.8 at the end of fiscal year the price was neutral
- Positive: 7.54 < Operating profit margin, % of 14.60
- Negative: Industry operating cash flow per share per price (median), % of 1.00 <= 5.42
- Positive: 1.77 < Return on assets ratio (scaled to [-100,100]) of 4.81
- Negative: Industry operating profit margin (median), % of -6.69 <= 2.95
- Positive: 42.53 < Shareholder equity ratio, % of 60.30 <= 64.17
- Negative: 0.01 < Interest expense per share per price, % of 0.12
- Positive: Inventory ratio change, % of 0.04 <= 0.82
- Positive: -14.19 < Investing cash flow per share per price, % of -5.52
- Negative: Industry earnings per price (median), % of 0 <= 0
Short-term STVN quotes
Long-term STVN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | €983.68MM | €1,085.35MM | €1,104.04MM |
| Operating Expenses | €791.25MM | €884.63MM | €942.89MM |
| Operating Income | €192.43MM | €200.72MM | €161.14MM |
| Non-Operating Income | €-4.79MM | €-11.17MM | €-0.85MM |
| Interest Expense | €3.94MM | €4.32MM | €6.86MM |
| R&D Expense | €34.39MM | €35.67MM | €31.67MM |
| Income(Loss) | €187.64MM | €189.55MM | €160.29MM |
| Taxes | €44.62MM | €43.86MM | €42.52MM |
| Profit(Loss)* | €142.85MM | €145.63MM | €117.78MM |
| Stockholders Equity | €996.13MM | €1,132.53MM | €1,404.34MM |
| Inventory | €213.25MM | €255.32MM | €245.22MM |
| Assets | €1,659.70MM | €2,071.58MM | €2,328.82MM |
| Operating Cash Flow | €103.31MM | €105.21MM | €155.78MM |
| Capital expenditure | €243.13MM | €441.93MM | €313.57MM |
| Investing Cash Flow | €-242.95MM | €-421.22MM | €-310.21MM |
| Financing Cash Flow | €-44.54MM | €158.03MM | €183.22MM |
| Earnings Per Share** | €0.54 | €0.55 | €0.43 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.